These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21575086)

  • 21. HDL particle subpopulations: Focus on biological function.
    Rached FH; Chapman MJ; Kontush A
    Biofactors; 2015; 41(2):67-77. PubMed ID: 25809447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant high-density lipoproteins and their use in cardiovascular diseases.
    Cao YN; Xu L; Han YC; Wang YN; Liu G; Qi R
    Drug Discov Today; 2017 Jan; 22(1):180-185. PubMed ID: 27591840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. American College of Cardiology--58th annual scientific session.
    Wong NC
    IDrugs; 2009 May; 12(5):291-3. PubMed ID: 19431092
    [No Abstract]   [Full Text] [Related]  

  • 24. Cholesterol efflux capacity as a novel biomarker for incident cardiovascular events: has high-density lipoprotein been resuscitated?
    Vallejo-Vaz AJ; Ray KK
    Circ Res; 2015 May; 116(10):1646-8. PubMed ID: 25953923
    [No Abstract]   [Full Text] [Related]  

  • 25. Mendelian randomization: how genetics is pushing the boundaries of epidemiology to identify new causes of heart disease.
    Thanassoulis G
    Can J Cardiol; 2013 Jan; 29(1):30-6. PubMed ID: 23199790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limits of Mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease.
    Rosenson RS; Hurt-Camejo E
    J Am Coll Cardiol; 2014 Mar; 63(9):942-3. PubMed ID: 24315918
    [No Abstract]   [Full Text] [Related]  

  • 27. HDL cholesterol efflux capacity and cardiovascular events.
    Kane JP; Malloy MJ; Pullinger CR
    N Engl J Med; 2015 May; 372(19):1871. PubMed ID: 25946301
    [No Abstract]   [Full Text] [Related]  

  • 28. HDL cholesterol efflux capacity and cardiovascular events.
    Rohatgi A; de Lemos JA; Shaul PW
    N Engl J Med; 2015 May; 372(19):1871-2. PubMed ID: 25946297
    [No Abstract]   [Full Text] [Related]  

  • 29. HDL cholesterol efflux capacity and cardiovascular events.
    Peters MN; Brook RD; Rajagopalan S
    N Engl J Med; 2015 May; 372(19):1869. PubMed ID: 25946298
    [No Abstract]   [Full Text] [Related]  

  • 30. HDL cholesterol efflux capacity and cardiovascular events.
    Kopecky C; Weichhart T; Säemann MD
    N Engl J Med; 2015 May; 372(19):1869. PubMed ID: 25946299
    [No Abstract]   [Full Text] [Related]  

  • 31. HDL cholesterol efflux capacity and cardiovascular events.
    Ritsch A; Scharnagl H; März W
    N Engl J Med; 2015 May; 372(19):1870-1. PubMed ID: 25946300
    [No Abstract]   [Full Text] [Related]  

  • 32. HDL cholesterol and apolipoprotein A-I concentrations and risk of atherosclerotic cardiovascular disease: Human genetics to unravel causality.
    Frikke-Schmidt R
    Atherosclerosis; 2020 Apr; 299():53-55. PubMed ID: 32178836
    [No Abstract]   [Full Text] [Related]  

  • 33. Biomarkers: Cholesterol efflux capacity--inverse association with incident cardiovascular disease.
    Holmes D
    Nat Rev Endocrinol; 2015 Feb; 11(2):64. PubMed ID: 25488484
    [No Abstract]   [Full Text] [Related]  

  • 34. Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.
    Rosenson RS; Koenig W
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):65-74. PubMed ID: 26797681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phospholipidation of HDL--how much is too much?
    Lagor WR; Rader DJ
    Clin Chem; 2011 Jan; 57(1):4-6. PubMed ID: 21078838
    [No Abstract]   [Full Text] [Related]  

  • 36. High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future.
    Julve J; Escolà-Gil JC
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of high-density lipoproteins in the regulation of angiogenesis.
    Tan JT; Ng MK; Bursill CA
    Cardiovasc Res; 2015 May; 106(2):184-93. PubMed ID: 25759067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mendelian Randomization.
    Birney E
    Cold Spring Harb Perspect Med; 2022 May; 12(4):. PubMed ID: 34872952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atherosclerosis: cholesterol efflux capacity-a new biomarker for cardiovascular risk?
    Duarte JH
    Nat Rev Cardiol; 2015 Jan; 12(1):2. PubMed ID: 25445136
    [No Abstract]   [Full Text] [Related]  

  • 40. Reply: limits of Mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease.
    Holmes MV; Simon T; Exeter HJ; Hingorani AD; Sabatine MS; Mallat Z; Casas JP; Talmud PJ
    J Am Coll Cardiol; 2014 Mar; 63(9):943. PubMed ID: 24315920
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.